Shape Therapeutics partnered with the Rett Syndrome Research Trust to advance SHP-401, an investigational one-time gene therapy for Rett syndrome. The collaboration is designed to support SHP-401’s development path, aligning the developer with a disease-focused stakeholder to help shape program priorities around outcomes and trial execution. The move continues a pattern of Rett-focused ecosystem building that seeks to accelerate translational milestones and patient-aligned endpoints in rare disease gene therapy.